This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Genentech USA, Inc.
Genentech USA, Inc., a pioneering biotechnology company, is headquartered in South San Francisco, California. Founded in 1976, Genentech has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for serious medical conditions, particularly in oncology, immunology, and neuroscience. With a commitment to research and development, Genentech has introduced groundbreaking products such as Herceptin and Avastin, which have transformed treatment protocols for various cancers. The company is renowned for its robust pipeline and dedication to personalised medicine, setting it apart in a competitive market. Recognised for its contributions to healthcare, Genentech has received numerous accolades, solidifying its position as a key player in the biotechnology sector. Its ongoing commitment to scientific advancement continues to drive its success and influence in the industry.
DitchCarbon Score
How does Genentech USA, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genentech USA, Inc.'s score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genentech USA, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Roche Holding AG, which influences its climate commitments and emissions reporting. As part of its parent company's sustainability initiatives, Genentech adheres to reduction targets and climate strategies set by Roche Holding AG. These initiatives include commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are cascaded from Roche. However, specific reduction targets or achievements for Genentech itself have not been disclosed. While no absolute emissions figures are provided, Genentech's alignment with Roche's broader climate strategies indicates a commitment to addressing carbon emissions and enhancing sustainability practices within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 249,350,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 114,452,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 6,402,719,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genentech USA, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
